Navigation Links
GenVec Reports Third Quarter 2009 Financial Results
Date:11/5/2009

ds. The decrease in both periods is primarily due to lower personnel costs, professional fees, reduced patient, site, lab, data management, monitoring and materials costs related to our TNFerade(TM) program, reduced materials costs related to our funded programs, and reduced general lab materials and supplies.

GenVec ended the third quarter of 2009 with $14.2 million in cash and investments.

"Based on existing contracts and collaborations, we anticipate revenues for 2009 will be between $14.0 million and $16.0 million. We project our cash burn to be between $12.0 million and $14.0 million for the 12 months ending September 30, 2010 although our spending will be heavily influenced by the availability of capital," commented Douglas J. Swirsky, GenVec's Senior Vice President and Chief Financial Officer. "Our primary focus remains on TNFerade and the PACT trial and we look forward to sharing additional data from this pivotal trial next year."

Third Quarter and Recent Highlights

  • GenVec has enrolled 277 patients in the pivotal PACT trial as of October 31, 2009.
  • GenVec's lead product candidate, TNFerade, was granted orphan drug designation by the FDA. Orphan drug designation provides potential financial and regulatory incentives including study design assistance, waiver of FDA user fees, tax credits, and up to seven years of market exclusivity upon marketing approval.
  • GenVec signed a contract with the SAIC for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH). This four-year contract has a total value of over $22 million if all options are exercised. Over the next year, GenVec will receive approximately $2.6 million under the base year of the contract.
  • GenVec was awarded an approximately $2.5 million Small Business Innovation and
    '/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... -- Neogen Corporation (Nasdaq: NEOG ) advised market ... from new rodenticide research are premature. In its regular ... 22, 2014, Neogen,s CEO commented about several new developments ... "It was my intent Tuesday at our conference call ... type of rodenticide, but certainly not to give any ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... health officials may not be saying it, but they are ... the deadly avian flu virus begins quietly in scattered areas ... handle on it - with substantial harm done to public ... and one that is exacerbated by the lack of an ...
... - Last Sunday morning, in the free-wheeling environment ... shared secrets and strategies from her forthcoming book, titled ... she expects to publish next year. , ,In her ... Huber provided advice about maximizing efficiency and minimizing hurt ...
... including one from California, to stem cell patents held ... lack merit and underscore the need for serious patent ... of challenging patents, such as those held by WARF, ... the United States Patent and Trademark Office ...
Cached Biology Technology:UW compound counters Avian flu 2UW compound counters Avian flu 3BarCamp talk turns to Internet dating 2BarCamp talk turns to Internet dating 3WARF challenges show need for patent reform 2WARF challenges show need for patent reform 3WARF challenges show need for patent reform 4
(Date:7/24/2014)... molecules, which have similar counterparts in humans, affect the ... nerve signals into the hippocampus, an area of the ... and the creation of memories. The results of the ... . , Brain function depends on the active communication ... neurons are woven together into a dense network where ...
(Date:7/24/2014)... Mass. (July 24, 2014) For years, researchers and ... forming nearly any cell type in the bodycould provide ... treat them. Yet progress has been hampered by the ... studies to their human counterparts, in part because human ... mouse cells. , Now Thorold Theunissen, Benjamin Powell, and ...
(Date:7/24/2014)... the University of York has carried out the first ... Ocean. , The results, reported in the journal ... the management of marine protected areas, with almost half ... in the region now under local community stewardship. , ... and coasts designed to protect wildlife from damage and ...
Breaking Biology News(10 mins):A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Western Indian Ocean communities play vital role in conservation 2
... or a fearless person - such individual differences in personality ... humans, it is hard to prove the existence of such ... influence human behaviour and these factors are hard to control ... they also have different personalities. , An international team ...
... bout of painful cold sores brought on by the Herpes ... infection, the virus usually remains in the body, hiding out ... reach it, causing no symptoms at all. , In order ... virus works to silence genes that would cause it to ...
... and the University of Rhode Island have demonstrated a new ... piece of protein that acts like a nanosyringe to deliver ... Proceedings of the National Academy of Sciences. , The researchers ... can be injected into the abdomen of a mouse, find ...
Cached Biology News:'Personality-gene' makes songbirds curious 2'Insulator' helps silence genes in dormant herpes virus 2'Insulator' helps silence genes in dormant herpes virus 3pHLIP, a novel technology to locate and treat tumors 2
...
... cytostatic and anti-viral agent. Inhibits several important steps ... formation of HUVEC cells. Also reduces intracellular reactive ... IL-8 release of endothelial cells. ... 16 O 8 MolWeight: ...
... includes the pZErO-1 vector with Zeocin resistance ... vector utilizes positive selection to eliminate high ... resistance gene reduces the overall vector size ... kit contains all of the reagents you ...
NATIVE, ENZYME PORCINE TRYPSIN...
Biology Products: